COSM Cosmos Health Inc.
Wholesale-Drugs, Proprietaries & Druggists' Sundries · Nasdaq · SEC CIK 1474167 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY33.8%
TTM net income YoY-13.1%
TTM EPS YoY35.6%
Revenue 3-yr CAGR14.8%
Net income 3-yr CAGR—
Margins
Gross margin10.3%
Operating margin-24.9%
Net margin-33.1%
FCF margin-13.5%
EBITDA margin-23.0%
Returns
ROE-104.0%
ROA-39.6%
ROIC (approx.)-54.8%
Asset turnover1.20x
Leverage & solvency
Liabilities / assets66.4%
Debt / equity0.15x
Current ratio1.05x
Interest coverage-7.80x
Cash quality & payout
Operating cash flow / net income0.40x
Accruals ratio-23.6%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $18.99M | $17.93M | $19.70M | $17.11M | $14.75M | $13.71M | $14.22M | $12.41M |
| Cost of revenue | $17.47M | $16.55M | $17.62M | $14.51M | $13.58M | $11.66M | $13.22M | $11.20M |
| Gross profit | $1.51M | $1.38M | $2.08M | $2.60M | $1.16M | $2.05M | $1.00M | $1.21M |
| R&D expense | $68,552 | $0 | $410,760 | $18,337 | $74,637 | $15,629 | $533,293 | $0 |
| SG&A expense | $2.07M | $1.80M | $10.61M | $2.04M | $1.49M | $1.48M | $7.14M | $1.78M |
| Operating income | -$2.93M | -$2.18M | -$11.41M | -$1.82M | -$2.65M | -$833,145 | -$8.97M | -$2.24M |
| Interest expense | $602,364 | $423,229 | $654,801 | $669,150 | $388,814 | $187,107 | $319,767 | $181,429 |
| Pretax income | -$6.09M | -$2.81M | -$10.15M | -$5.35M | -$2.83M | -$818,097 | -$9.54M | -$2.18M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$6.09M | -$2.81M | -$10.15M | -$5.35M | -$2.83M | -$818,097 | -$9.54M | -$8.38M |
| EBITDA | -$2.58M | -$1.84M | -$11.09M | -$1.44M | -$2.29M | -$517,309 | -$8.66M | -$1.94M |
| EPS (basic) | -0.10 | -0.06 | — | -0.17 | -0.10 | -0.03 | — | -0.45 |
| EPS (diluted) | -0.10 | -0.06 | — | -0.17 | -0.10 | -0.03 | — | -0.45 |
| Weighted avg. shares (diluted) | 59.92M | 47.09M | — | 30.63M | 28.75M | 26.04M | — | 18.42M |
| Balance sheet | ||||||||
| Cash & equivalents | $1.80M | $514,702 | $715,674 | $889,441 | $655,503 | $742,881 | $315,105 | $3.31M |
| Short-term investments | $37,464 | $34,225 | $46,158 | $33,178 | $30,266 | $25,278 | $21,148 | $22,808 |
| Receivables | $18.86M | $18.19M | $19.63M | $18.03M | $15.46M | $14.25M | $13.48M | $17.48M |
| Inventory | $4.52M | $5.65M | $5.78M | $5.68M | $5.11M | $4.74M | $4.36M | $4.89M |
| Current assets | $36.67M | $36.89M | $38.39M | $38.10M | $30.56M | $27.84M | $25.46M | $36.24M |
| PP&E, net | $10.14M | $10.28M | $10.58M | $10.66M | $10.82M | $10.02M | $9.69M | $10.58M |
| Goodwill | $49,697 | $49,697 | $49,697 | $49,697 | $49,697 | $49,697 | $49,697 | $49,697 |
| Intangibles | $6.92M | $7.18M | $7.52M | $7.91M | $8.18M | $7.75M | $7.71M | $7.70M |
| Total assets | $61.46M | $62.37M | $65.48M | $69.49M | $61.84M | $57.19M | $54.31M | $64.52M |
| Current liabilities | $34.84M | $34.08M | $38.27M | $38.53M | $31.17M | $26.59M | $25.76M | $25.21M |
| Long-term debt | $3.19M | $3.45M | $3.78M | $5.37M | $5.19M | $4.85M | $4.11M | $4.27M |
| Total debt | $3.19M | $3.45M | $3.78M | $5.37M | $5.19M | $4.85M | $4.11M | $4.27M |
| Total liabilities | $40.79M | $42.54M | $47.05M | $46.36M | $35.60M | $31.24M | $29.78M | $29.54M |
| Shareholders' equity | $20.67M | $19.83M | $18.42M | $23.13M | $26.23M | $25.95M | $24.53M | $34.98M |
| Net debt | $1.39M | $2.94M | $3.06M | $4.48M | $4.54M | $4.11M | $3.79M | $953,127 |
| Shares outstanding | 80.67M | 41.07M | 41.07M | 31.87M | 29.72M | 27.20M | 23.60M | 23.26M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.72M | -$1.07M | -$4.60M | -$2.46M | -$1.21M | -$186,316 | -$3.83M | $739,774 |
| Capital expenditure | $63,637 | $11,399 | $7,895 | $12,716 | $22,534 | $12,530 | $72,482 | $228,767 |
| Free cash flow | -$1.78M | -$1.08M | -$4.60M | -$2.47M | -$1.23M | -$198,846 | -$3.91M | $511,007 |
| Investing cash flow | $114,605 | -$708,963 | -$1.07M | -$1.01M | $71,820 | -$7,069 | -$1.01M | -$35,433 |
| Financing cash flow | $1.79M | $347,627 | $4.70M | $7.19M | $1.60M | $560,862 | $1.62M | $2.68M |
| Depreciation & amortization | $349,181 | $346,520 | $315,145 | $377,911 | $353,862 | $315,836 | $304,862 | $304,139 |
| Stock-based compensation | $558,858 | $535,786 | $582,008 | $0 | $0 | $556,611 | $586,512 | $0 |
| Share buybacks | — | — | — | — | — | — | $0 | — |
Free plan shows the latest 8 periods; Pro shows all 68 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.